Valye reports for unlimited access

CapsoVision develops and commercializes advanced capsule endoscopy systems for diagnosing abnormalities in the gastrointestinal tract. Its flagship product, CapsoCam Plus, is a single-use capsule that captures 360° panoramic video of the small bowel mucosa, enabling superior diagnostic yield compared to traditional end-view capsules. The system includes software platforms CapsoCloud and CapsoView for video review and analysis, supporting telemedicine and remote ingestion. The company is advancing AI-assisted pathology detection technology to enhance diagnostic efficiency and accuracy. CapsoVision is also developing the CapsoCam Colon capsule, designed to visualize the colon and detect polyps using AI and 3D sensing technology. The company sells primarily to gastroenterologists in clinics and hospitals, using a direct sales model in the U.S. and distributors internationally. Manufacturing relies on single-source suppliers in Asia, with assembly completed in the U.S. The company has a history of net losses and requires additional financing to support growth and product development.

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing oral delivery technology for biologics and drugs to provide a convenient alternative to injections. Its proprietary platform, the RaniPill capsule, has two configurations: RaniPill GO for microtablet delivery and RaniPill HC for high-capacity liquid payloads. The company is advancing multiple pipeline programs including RT-114 (GLP-1/GLP-2 dual agonist for obesity), RT-116 (semaglutide for obesity), and RT-105 (anti-TNF-alpha antibody for inflammatory diseases). Rani Therapeutics has no approved products or commercial revenue and is pursuing partnerships and collaborations, including a key agreement with Chugai Pharmaceutical. The company employs a vertically integrated manufacturing strategy with plans for automated production lines. Financially, as of December 31, 2025, it held $18.6 million in cash and equivalents, had no outstanding debt, and reported a net loss of $29.7 million for the fiscal year. Recent leadership changes and financing activities have been reported.

Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharmaceutical company developing treatments for rare diseases, with a focus on Netherton Syndrome. Its lead product candidate, QRX003, is a topical lotion formulated with a broad-spectrum serine protease inhibitor and proprietary technology. The company has received orphan drug designation in Europe and a Rare Pediatric Disease designation from the FDA for QRX003. It has initiated pivotal clinical trials following FDA clearance and is preparing for a Phase 3 trial. The company has filed patent applications to protect its intellectual property. Quoin Pharmaceuticals has not yet generated revenue and has incurred significant net losses since inception. It maintains liquidity through cash, short-term investments, and recent private placements. The company faces typical risks of clinical-stage biopharmaceutical firms, including regulatory, financial, operational, and competitive challenges.

Worksport Ltd is a company focused on designing, developing, and manufacturing innovative automotive accessories and clean energy products. Its core product lines include soft and hard folding tonneau covers for light trucks, solar-integrated tonneau covers (SOLIS), portable energy storage systems (COR), and advanced heat pump systems developed by its subsidiary Terravis Energy. The company operates manufacturing and assembly facilities in the U.S. and maintains a diversified supplier network to mitigate supply chain risks. Worksport has expanded its dealer network significantly and pursues both business-to-business and direct-to-consumer sales channels. The company has a substantial intellectual property portfolio protecting its innovations and continues to invest in research and development and manufacturing scale-up. Worksport has raised capital through at-the-market offerings and warrant inducements to support its operations and growth initiatives. The company faces competitive pressures in both the tonneau cover and portable power station markets and operates with a history of operating losses and financing reliance.

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for orphan pulmonary and fibrosis indications with limited or no approved treatments. Its lead candidate, LTI-03, is a peptide drug derived from the Cav1 protein, targeting idiopathic pulmonary fibrosis (IPF). LTI-03 has orphan drug designation in the U.S. and EU and has completed Phase 1a and 1b clinical trials demonstrating safety, tolerability, and positive biomarker activity related to fibrosis reduction and epithelial cell protection. The company initiated a Phase 2 RENEW trial in 2025, enrolling IPF patients across multiple countries, with regulatory clearances from FDA, EMA, MHRA, and others. Development of LTI-01, targeting loculated pleural effusion (LPE), is paused indefinitely due to capital limitations. Rein Therapeutics has no approved products or revenues and relies on external funding to support clinical development and operations. The company rebranded from Aileron Therapeutics in January 2025 to focus on pulmonary and fibrosis therapies.

Chaince Digital Holdings Inc. is a Cayman Islands holding company conducting operations primarily through its subsidiaries in the United States, Hong Kong, and China. Historically engaged in blockchain and digital asset mining activities, including Bitcoin and Filecoin mining, the company strategically discontinued all digital asset mining operations in December 2025 to focus on financial services and advisory businesses. The current core operations include financial advisory, capital markets advisory, brokerage-related services, and corporate consulting, delivered mainly through its U.S. subsidiaries Chaince Securities, Inc. and Chaince Securities, LLC (a FINRA-registered broker-dealer and registered investment advisor), and Ucon Capital (HK) Limited. The company serves corporate clients and institutional investors primarily in North America, Greater China, and Southeast Asia. Revenue is project-based and transaction-driven, with a client base of over 20 corporate clients as of the end of 2025. The company completed several private placements in 2025 and early 2026, raising capital through share issuances. As of December 31, 2025, the company held strong liquidity with cash and equivalents of approximately $33.8 million and a current ratio of 25.71, but reported a net loss of about $5.1 million for the year. The company is completing an orderly wind-down of discontinued digital asset mining operations and continues to hold certain digital assets and stablecoins as part of treasury and investment activities. Marketing efforts focus on relationship-driven client acquisition and strategic partnerships, leveraging a global presence. The company operates in a highly competitive financial services industry and faces risks related to limited operating history in its current core business, revenue fluctuations, client concentration, competition, regulatory compliance, and digital asset volatility.

Borr Drilling Ltd operates as an offshore drilling contractor, providing drilling services primarily for the oil and gas industry. Incorporated in Bermuda, the company’s shares trade on the New York Stock Exchange and Euronext Growth Oslo, with plans to up-list on the Oslo Stock Exchange. The company’s business model centers on owning and operating offshore drilling rigs, generating revenue through drilling contracts with energy companies. Borr Drilling’s financial reporting follows U.S. GAAP standards, and it maintains governance policies including insider trading and ethics codes. The company manages market risks such as foreign currency exposure and interest rate fluctuations, with a focus on maintaining liquidity and operational efficiency. Leadership includes CEO Bruno Morand, appointed in 2025 with extensive industry experience. Borr Drilling’s shareholder base includes significant institutional investors and insiders, reflecting active market interest.

Amazon.com, Inc. is a leading global internet retailer and cloud services provider. Its business model includes e-commerce platforms, Amazon Web Services (AWS) cloud computing, and expanding healthcare offerings such as pharmacy services. The company engages in strategic investments and partnerships, notably a significant equity commitment to OpenAI, reflecting a focus on artificial intelligence integration. Amazon's financial position as of the end of 2025 shows strong liquidity and profitability, supported by diversified revenue streams and capital market activities.

Austin Gold Corp. is a foreign private issuer headquartered in Vancouver, Canada, engaged in gold exploration activities primarily in Nevada, United States. The company files annual reports on Form 20-F and periodic reports on Form 6-K with the SEC, providing financial statements and operational updates. Its key projects include Kelly Creek, Stockade Mountain, Lone Mountain, and Fourmile Basin. Financial disclosures indicate the company is in a development stage with no reported revenue but incurs operating losses. The company maintains liquidity through cash and current assets, though detailed liabilities and liquidity ratios are not disclosed.

Global-E Online Ltd. provides an integrated global e-commerce platform designed to simplify international online shopping and selling. The platform localizes the shopper experience by offering native language support, market-adjusted pricing, local payment options, compliance with local regulations including customs duties and taxes, shipping, after-sales support, and returns management. The company generates revenue primarily through service fees based on transaction values processed on its platform and through optional fulfillment services such as shipping and handling. As of December 31, 2025, Global-E served 1,547 merchants across more than 30 countries, with significant geographic diversification in both merchant origin and destination markets. The company has made strategic acquisitions, including ReturnGo Ltd., to enhance its post-purchase solutions and maintains partnerships such as with Shopify for managed international markets. The executive leadership team includes experienced co-founders and senior officers with backgrounds in banking, technology, and global sales.

Kornit Digital Ltd. is an Israeli company incorporated in 2002 and publicly traded on Nasdaq since 2015 under the ticker KRNT. It specializes in digital printing solutions for the printed textile industry, focusing on the rapidly growing direct-to-garment (DTG) and direct-to-fabric segments. The company’s product portfolio includes proprietary digital printing systems, curing systems, inks, consumables, software, and value-added services. Kornit's patented wet-on-wet printing technology eliminates the need for fabric pre-treatment, enabling high-quality printing on a variety of untreated fabrics. The company serves fulfillers and demand generators such as brands and content creators primarily in fashion, apparel, and home décor. Kornit’s business model leverages a growing installed base of systems to drive recurring sales of ink and consumables. In 2024, Kornit introduced the All-Inclusive Click (AIC™) model, offering customers a full solution with fixed price per impression and minimum annual commitments, enhancing revenue predictability. The company employs a hybrid sales model combining direct sales and channel partners globally. Maintenance and support are provided through a mix of internal teams and distributor-employed engineers. Kornit operates in a market characterized by strong growth in digital textile printing, driven by e-commerce expansion, social media influence, and sustainability trends. The company reported $208.2 million in revenue and a net loss of $13.5 million for the year ended December 31, 2025, with a strong liquidity position and ongoing capital expenditures focused on equipment production for lease.

ELTEK LTD, incorporated in 1970 and headquartered in Israel, specializes in manufacturing technologically advanced custom printed circuit boards (PCBs), including rigid, flexible, and flex-rigid types with up to 40 layers. The company targets short run, prototype, pre-production, and low to medium volume production primarily for high-growth advanced electronics applications. Its customer base spans defense and aerospace, medical equipment, industrial equipment, and other sectors, with sales concentrated in Israel and international markets including North America and Europe. ELTEK holds key certifications such as ITAR registration and Nadcap accreditation, supporting its focus on high-reliability applications. The company has invested significantly in production equipment and infrastructure to enhance capacity and technological capabilities. Financially, ELTEK reported $51.79 million in revenues and $0.826 million net income for 2025, with a strong liquidity position and no outstanding bank debt. Marketing and sales efforts include direct personnel and partnerships with distributors and manufacturers globally [S1].

WEN Acquisition Corp is a Cayman Islands exempted blank check company incorporated in January 2025 to effect a business combination with one or more businesses, primarily targeting fintech infrastructure companies focused on digital assets and blockchain integration. The company completed its IPO in May 2025, raising approximately $300 million, which is held in a trust account. The management team, led by CEO Julian M. Sevillano and CFO Jurgen van de Vyver, has extensive experience in fintech, payments, stablecoins, and digital assets, supported by advisors with SPAC expertise. The company has no operating revenues and has not yet selected a business combination target. It must complete a business combination by May 19, 2027, or liquidate and return funds to shareholders. The company’s acquisition criteria emphasize cash flow growth, strong management, public company advantages, and blockchain-based competitive advantages. As of December 31, 2025, the company had strong liquidity with a current ratio of 5.19 and reported net income for the fiscal year, though EPS was negative in Q1 2025. The company announced a trading separation of Class A shares and warrants effective July 7, 2025.

Globa Terra Acquisition Corp is a Cayman Islands exempted blank check company incorporated in October 2024 to effect a merger or similar business combination. It has not commenced operations or generated revenue and focuses on identifying a target business primarily in the agribusiness and water sectors across the Americas. The company completed its IPO in July 2025, raising approximately $175 million, which is held in a trust account invested in U.S. government securities. The company’s strategy includes targeting companies with strong fundamentals, multi-country operations, and ESG integration, aiming to create long-term value through private equity-style operational enhancements. The management team has significant SPAC and public company experience, which supports sourcing and executing transactions.

Churchill Capital Corp XI is a Cayman Islands exempted blank check company (SPAC) incorporated in June 2025. Its purpose is to identify and complete an initial business combination with one or more target companies in any industry. The company completed its IPO in December 2025, issuing 41.4 million units and raising $414 million, which is held in a Trust Account. The management team, led by Michael Klein and supported by M. Klein and Company and Archimedes Advisors LLC, leverages extensive industry and operational experience to source and evaluate acquisition targets. The company has not yet selected a target and has generated no operating revenues. It must complete a business combination by December 18, 2027, or face liquidation and distribution of Trust Account funds to shareholders. The company maintains strong liquidity with a current ratio of 8.13 as of December 31, 2025.

Proem Acquisition Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in July 2025. It completed its initial public offering in February 2026, issuing units consisting of ordinary shares and redeemable warrants, raising gross proceeds of $130 million plus a private placement. The company has not commenced operations or selected a business combination target as of the latest filing. Its business strategy focuses on acquiring a high-growth, disruptive technology company, leveraging the expertise of its sponsor, Proem Asset Management, a technology-focused investment firm. The company targets sectors including artificial intelligence, blockchain, SaaS, data infrastructure, and cybersecurity. It has a 24-month window from the IPO to complete a business combination, with provisions for shareholder redemptions and potential liquidation if no combination is completed. The company currently generates no operating revenues and holds IPO proceeds in a trust account.

NU RIDE INC., formerly Lordstown Motors Corp., emerged from Chapter 11 bankruptcy in March 2024. Post-emergence, the company’s operations focus on resolving bankruptcy claims, prosecuting ongoing litigation including a significant case against Foxconn, managing retained causes of action, and exploring potential strategic alternatives or business combinations. The company’s assets include cash, short-term investments, loans receivable related to billboard leasehold assets, and net operating loss carryforwards. NU RIDE does not currently generate revenue and operates as a single segment focused on claims administration and litigation management. The company relocated its headquarters to New York, New York, and had one full-time employee as of March 2026.

Southland Holdings, Inc. is a diversified leader in specialty infrastructure construction with a history dating back to 1900. Headquartered in Grapevine, Texas, Southland operates primarily in North America through its two main segments: Civil and Transportation. The Civil segment focuses on water infrastructure projects including pipelines, treatment plants, and tunneling, while the Transportation segment specializes in bridges, roadways, marine facilities, and specialty structures. The company serves a mix of public and private customers, including federal and state agencies, local transit authorities, utilities, and private industrial and commercial owners. Southland emphasizes self-performance to control costs and quality, and has recently exited certain Materials & Paving activities to concentrate on more profitable lines. The company’s contracts are primarily fixed-price and obtained through competitive bidding or direct negotiation. Revenue recognition follows ASC 606 standards. Southland faces seasonal and weather-related variability, competitive pressures, and market risks such as interest rate fluctuations. The company reported $772.2 million in revenue and a net loss of $308.4 million for the year ended December 31, 2025, with liquidity challenges addressed through credit agreement amendments and surety support.

SpyGlass Pharma, Inc. focuses on developing long-acting, sustained drug delivery systems for chronic eye conditions. Its lead candidate, the BIM-IOL System, integrates proprietary drug pads with an intraocular lens implanted during cataract surgery to deliver bimatoprost over three years, targeting patients with open-angle glaucoma or ocular hypertension. The company is conducting Phase 3 clinical trials and plans to submit a New Drug Application following successful trial completion. SpyGlass Pharma has no commercial products or revenues and has historically incurred significant losses. It relies on third-party manufacturers and holds exclusive intellectual property licenses critical to its technology. The company completed its IPO in early 2026 and has attracted multiple analyst coverage initiations with positive recommendations.

GP-Act III Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. Its business model is to identify and complete a business combination with one or more target companies. The company completed its IPO in May 2024, raising gross proceeds of approximately $287.5 million. It holds these proceeds in a trust account invested mainly in Treasury securities and money market funds. The company has not commenced any operating activities or generated operating revenues as of June 30, 2025. Its income is derived from interest earned on the trust account. The company has incurred general and administrative expenses related to its formation and IPO activities. It is classified as an emerging growth company and has elected to use the extended transition period for new accounting standards. The company has outstanding Class A and Class B ordinary shares, with Class A shares subject to possible redemption. It has related party loans to finance transaction costs, which are non-interest bearing and payable upon consummation of a business combination or the second anniversary of the IPO.

Seafarer Exploration Corp focuses on rescue archaeology and the archaeologically-sensitive exploration, recovery, and conservation of historic shipwrecks. The company aims to monetize recovered artifacts after conservation and scientific research. It conducts extensive archival research and develops proprietary technology, notably the SeaSearcher, to enhance exploration accuracy and efficiency. The business involves a multi-year, multi-stage process with high uncertainty and significant financial and operational risks. Seafarer holds permits for exploration and recovery at sites such as Juno Beach and Melbourne Beach and has exclusive rights to conduct recovery operations at the Juno Beach wreck site. The company also engages in media initiatives to promote its activities.

DBV Technologies S.A. operates as a biotechnology company specializing in the research and development of epicutaneous immunotherapy products, with a primary focus on the Viaskin Peanut patch for peanut allergy treatment. The company is transitioning from a development-stage to a potential commercial-stage organization, evidenced by recent executive appointments and commercial strategy initiatives. DBV Technologies conducts clinical trials including the Phase 3 VITESSE study and the COMFORT Toddlers study, with recent positive topline results reported. The company has established manufacturing and supply agreements, notably with SANOFI, to support production capacity. Financially, DBV Technologies reported no operating revenue in 2025 aside from a French research tax credit, while incurring significant operating expenses primarily related to research and development, sales and marketing, and general administration. The company raised substantial capital through PIPE and ATM equity offerings, resulting in a strong cash position at the end of 2025. DBV Technologies is preparing for potential regulatory approvals and commercial launch in North America and Europe, with ongoing investments in inventory, manufacturing, and organizational scaling.

Abercrombie & Fitch Co. is a Delaware-incorporated global retailer specializing in apparel, personal care products, and accessories for men, women, and children. The company operates an omnichannel business model, selling primarily through its own stores and digital platforms, supplemented by third-party arrangements. It manages its operations across three geographic segments: Americas, EMEA, and APAC. The company’s brand portfolio includes Abercrombie and Hollister, both targeting customers seeking quality and style. Revenue is recognized upon transfer of control to customers, net of returns and discounts. The company invests in store experiences and digital initiatives to support growth and customer engagement. Segment reporting and financial disclosures provide detailed insights into sales, costs, and operating income by region. The company also maintains a share repurchase program to return capital to shareholders.

Dermata Therapeutics, Inc. is focused on developing and commercializing skincare products addressing common and underserved skin conditions. Initially focused on prescription (Rx) products, Dermata's lead asset was XYNGARI (DMT310), a topical acne treatment studied in Phase 3 clinical trials with positive results announced in March 2025. In September 2025, the company strategically shifted to developing direct-to-consumer (DTC) and business-to-business (B2B) over-the-counter (OTC) skincare products leveraging its proprietary Bioneedle technology derived from Spongilla lacustris, a freshwater sponge. This shift aims to accelerate commercialization, reduce regulatory burden, and lower development costs. Dermata plans to launch its first cosmetic product, a foundational skin renewal treatment, in mid-2026, followed by an OTC acne clearing treatment. The company intends to market products through its website and professional channels including aestheticians and dermatologists, supported by a certification program. Dermata also explores expanding its product portfolio to address other skin conditions such as psoriasis and seborrheic dermatitis. The company maintains an exclusive supply agreement for its Spongilla raw material and is engaged in a license dispute with Villani, Inc. regarding the strategic shift. Dermata reported a net loss of $7.6 million for fiscal 2025 and held $7.5 million in cash at year-end, with strong liquidity ratios. The company announced a private placement valued at up to $12.4 million in December 2025. Dermata operates in a competitive skincare market with risks including regulatory challenges, competition, supply chain dependencies, and operational execution.

Oramed Pharmaceuticals Inc. develops orally digestible pharmaceutical products, with a focus on oral insulin delivery. The company relies on strategic partnerships and joint ventures for development, commercialization, and marketing, lacking its own large-scale manufacturing and sales infrastructure. It has invested in clinical-stage oncology company Alpha Tau and transferred POD technology to Lifeward, gaining significant equity stakes. Oramed reported net income and revenues for fiscal 2025, supported by strong liquidity. The company faces industry competition, regulatory hurdles, and operational risks including personnel retention and currency exposure. It also invests in real estate assets, adding market and liquidity risk exposure.

CV Sciences, Inc. operates as a consumer wellness company focused on hemp-derived nutraceuticals and plant-based foods. Its product portfolio includes hemp extracts, cannabinoid-free supplements, plant-based protein products, and encapsulated softgels and tinctures. The company sells through diverse channels including retail stores, distributors, and e-commerce platforms across North America and Europe. Key brands include +PlusCBD™, +PlusHLTH™, Cultured Foods™, and Lunar Fox™. CV Sciences has made strategic acquisitions to expand its manufacturing and product capabilities, including Cultured Foods in Poland and Elevated Softgels in Colorado. The company emphasizes scientific validation, quality assurance, and regulatory compliance in its operations. It faces a competitive market landscape and evolving regulatory frameworks that influence its business environment.

Buda Juice, Inc. is a beverage company focused on producing and distributing UltraFresh™ cold-crafted citrus juices, lemonades, and wellness shots. Founded in 2013 and headquartered in Dallas, Texas, the company transitioned from retail storefronts to selling through grocery retailers, emphasizing a continuous cold chain from orchard to shelf to preserve freshness, taste, and nutrients. Its product portfolio includes organic wellness shots, value-forward non-organic citrus juices, and private label products. The company operates an asset-light model with a high-tech, SQF Level II certified production facility and outsources logistics. Buda Juice's strategic growth plan involves expanding its geographic footprint through a three-hub model serving large U.S. population centers. The company reported net income of $3.53 million for fiscal 2025 and maintains strong liquidity. It faces competition from larger beverage companies and depends on a limited number of customers while working to diversify its customer base.

WRAP TECHNOLOGIES, INC. operates as a global public safety technology and services company delivering integrated non-lethal solutions for law enforcement, corrections, defense, and public safety organizations. Its product portfolio centers on the BolaWrap non-lethal device line, designed to provide a controlled, non-pain-compliance option for officers to gain tactical advantage and reduce use-of-force incidents. Complementing hardware offerings are software platforms such as Wrap Reality VR training and WrapTactics digital training, aimed at enhancing officer readiness and decision-making under stress. The company also offers WrapVision, a body-worn camera and digital evidence management solution assembled in North America to meet federal procurement and data sovereignty requirements. Expanding into emerging markets, WRAP is developing counter-unmanned aircraft system (C-UAS) technologies leveraging proprietary tether deployment for non-lethal drone interdiction. The company’s sales approach integrates product sales with technology-enabled services, targeting U.S. federal, state, local, and international law enforcement agencies, correctional facilities, and defense sectors. Manufacturing is conducted domestically with a new facility in Virginia to support scalable production. WRAP holds a substantial intellectual property portfolio and pursues strategic partnerships to broaden market access and product integration.

Newsmax Inc. operates through its subsidiary Newsmax Media, which produces and distributes original news and editorial content via multiple platforms including cable TV channels (Newsmax, Newsmax2, World at War), syndicated radio shows, podcasts, digital websites, and print publications. The Broadcasting segment generates revenue from advertising, subscriptions, and affiliate fees from MVPDs, with distribution to over 100 million U.S. homes and international licensing in over 100 countries. The Digital segment generates revenue from online advertising, paid subscriptions (including Newsmax+ streaming service and specialized newsletters), and e-commerce sales of nutraceuticals and books. Newsmax Media's subsidiaries include Humanix Publishing, Medix Select (nutraceuticals), Newsmax Digital Advertising, Newsmax Publications (paid subscriptions), ROI Media Strategies (media buying services), and Crown Atlantic Insurance (insurance marketing). The company completed a private placement and IPO in 2025, raising significant capital and listing on the NYSE under ticker NMAX. Revenue has grown substantially from 2020 to 2025, with advertising and subscription revenues as key drivers. The company targets an older demographic with significant disposable income and continues to expand distribution and content offerings across traditional and digital platforms.

Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands and listed on Nasdaq under the ticker OACC. The company issues units consisting of Class A ordinary shares and redeemable warrants. The filings do not provide detailed information on the company's business operations, products, or customers. Financial disclosures focus primarily on liquidity and net income figures, with no reported revenue. The company has experienced changes in its chief financial officer position during 2025. It is classified as an emerging growth company under SEC rules.

PAINREFORM LTD., now operating as PRF Technologies Ltd., is a specialty pharmaceutical company originally focused on reformulating established therapeutics to provide extended post-surgical pain relief with reduced opioid use. In 2025, the company expanded into the clean energy sector through the acquisition of DeepSolar, an AI-driven solar analytics technology business. The company is headquartered in Tel Aviv, Israel, and prepares its financial statements under U.S. GAAP. It reported minimal revenue and a net loss for fiscal year 2025, with liquidity ratios indicating a moderate ability to cover short-term liabilities.

Quantum Biopharma Ltd. operates as a biotechnology company with a focus on developing pharmaceutical therapies for neurodegenerative diseases. Its primary product candidate is Lucid-MS, a patented molecular compound targeting multiple sclerosis. The company conducts research and development through subsidiaries including Huge Biopharma in Australia and Lucid. It has paused some research programs due to funding constraints and suspended cannabis-related operations through FV Pharma. The company licenses intellectual property to Unbuzzd Wellness Inc. and Celly U.S. for consumer product commercialization, maintaining significant influence over Unbuzzd. Quantum Biopharma has no approved pharmaceutical products or commercial sales and continues to incur losses while funding operations through equity and debt financing. It holds a significant portion of its assets in cryptocurrency, which introduces financial statement volatility. The company is advancing Lucid-MS toward regulatory filings and clinical trials and is involved in ongoing litigation that could materially impact its financial condition. It rents office space in Toronto and does not own significant physical infrastructure [S1][S2].

Nyxoah SA develops and commercializes the Genio system, a medical device for treating obstructive sleep apnea (OSA). The company is headquartered in Belgium and has a senior management team with extensive experience in medical devices and commercialization. Nyxoah has expanded its commercial footprint with the launch of the Genio system in the Netherlands and has obtained favorable reimbursement rulings to support market access. The company finances its operations through equity and debt instruments, including convertible notes issued in late 2025. Financial disclosures indicate ongoing net losses as the company invests in commercialization and clinical development.

Evogene Ltd. is a biotechnology company headquartered in Israel, with a focus on developing and commercializing products in agriculture and human health. The company operates through subsidiaries including Biomica Ltd., which develops microbiome-based therapeutics, and Lavie Bio Ltd., which focuses on bio-fungicides. Evogene's business model includes licensing proprietary technologies and products to third parties, such as the exclusive worldwide license of BMC128 to Shanghai Lishan Biopharmaceuticals for cancer therapeutics. The company also engages in collaborations and consortiums to advance research in genome editing and precision agriculture. Evogene maintains a proprietary computational platform (CPB) that integrates big data and AI algorithms to support its R&D efforts. The company has received various government grants and participates in international research programs, which come with regulatory and royalty obligations under Israeli law. Financially, Evogene reported revenues of approximately $3.85 million and a net loss of $7.83 million for the fiscal year ended December 31, 2025, with a strong liquidity position evidenced by a current ratio of 4.54 and cash ratio of 3.76.

Nexa Resources S.A. operates integrated mining and smelting businesses focused on zinc, copper, silver, lead, and gold. The company’s mining operations produce concentrates that are either sold externally or supplied internally to its smelting operations. Smelting generates revenue from processing concentrates, capturing value from treatment charges, free metal, premiums, and by-products. Nexa’s sales are diversified geographically, with significant exposure to Peru, Brazil, the United States, and Asia. The company holds a large portfolio of mining concessions in Peru and Brazil, with ongoing exploration and project evaluation activities. Capital expenditures focus on sustaining current operations and advancing growth projects. Nexa manages financial risks through a comprehensive risk management framework and maintains liquidity through cash reserves and access to credit facilities. The company follows a dividend policy linked to free cash flow generation.

YPF SOCIEDAD ANONIMA operates a fully integrated oil and gas business in Argentina, with leading market positions across upstream, midstream, downstream, LNG, integrated gas, and new energies segments. The company’s hydrocarbon production is concentrated in the Neuquina, Golfo San Jorge, Austral, and Noroeste basins. As of December 31, 2025, YPF held substantial developed and undeveloped acreage, with a portfolio of exploration permits and exploitation concessions operated and non-operated. The company engages in joint ventures and contractual arrangements with varying ownership interests. In 2025, YPF drilled multiple wells and maintained active development and exploratory activities. Financially, the company reported $18.448 billion in revenue and a net loss of $799 million for the fiscal year ended December 31, 2025, with liquidity ratios below 1 indicating some short-term liquidity constraints. Recent news highlights operational developments including rig lease deals and strategic asset sales, as well as challenges such as lower hydrocarbon production impacting earnings.